Portolano Cavallo

Life Sciences

Blog

11 Jun
Online medicine sales and the processing of purchase data: The Court of Justice of the European Union rules
Data related to purchasing non-prescription medicine sold online by an authorized pharmacy should not be considered health-related data under the GDPR.
11 Jun
Medical research: Advance consultation with Data Protection Authority no longer required
Medical research is one of the sectors most affected by rapid technological development and the increasing use of artificial intelligence systems.
11 Jun
Artificial Intelligence in health care: Impact of the new draft law approved by the Italian Council of Ministers
The Italian Council of Ministers approved a draft law on principles governing artificial intelligence, designed to provide an initial national framework for artificial intelligence systems.
23 Apr
Italian Data Protection Authority publishes rules for platforms (websites or apps) connecting patients and healthcare professionals
The evolution of online platforms and apps that connect patients with healthcare professionals has made medical care more accessible, but it has also raised important issues concerning privacy and the protection of personal data.
15 Apr
“Pharmacy of Services”: Simplification Decree expands the range of healthcare and telemedicine services pharmacies can provide
The new draft of the Simplification Decree significantly expands the range of services that can be provided by pharmacies as part of the National Health Service.
4 Apr
Online sale of medicines without a prescription: The Court of Justice of the European Union approves intermediary sites
The Court of Justice of the European Union intervened on a major issue for the online medicine sales industry, paving the way for the entry of intermediary platforms.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on